

~~a first mobility-modifier comprising a first tail and a first tag complement for binding to the first tag; and
a second complex comprising:
a second probe comprising a second target-specific portion for sequence-specific hybridization to a second target nucleic acid sequence, and a second tag; and
a second mobility-modifier comprising a second tail and a second tag complement for binding to the second tag;
wherein a mobility of the first complex in a mobility-dependent analysis technique is distinguishable from a mobility of the second complex in the mobility-dependent analysis technique; and
wherein the first complex and the second complex are present as a mixture.~~

2. (Once Amended) The composition of **claim 1** wherein the first target-specific portion comprises polynucleotide.

B1
with
3. (Once Amended) The composition of **claim 2** wherein the first target-specific portion comprises a 3'-hydroxyl group.

4. (Once Amended) The composition of **claim 2** wherein the first target-specific portion comprises PNA.

5. (Once Amended) The composition of **claim 1** wherein the first tag portion comprises polynucleotide.

6. (Once Amended) The composition of **claim 5** wherein the first tag portion comprises PNA.

7. (Once Amended) The composition of **claim 1** wherein the first tag complement portion is PNA.

8. (Once Amended) The composition of **claim 1** wherein both the first tag and first tag complement are polynucleotide, and one of the first tag complement and first tag comprises a sequence selected from the group consisting of $(CAG)_n$ and $(TCC)_n$ wherein n is 1 to 10.

9. (Once Amended) The composition of **claim 1** wherein the first mobility modifier comprises a tail portion that is at least partially not polynucleotide.

10. (Once Amended) The composition of **claim 1** wherein the first tail is a polymer.

11. (Once Amended) The composition of **claim 10** wherein the polymer is selected from the group consisting of polyethyleneoxide and polypeptide.

II. REMARKS

Claims 1-11 have been amended. Claims 1-12 are pending.

Rejections under 35 U.S.C. § 102(b)

A. REJECTION BASED ON GROSSMAN

At paragraph 3 of the Office Action, the examiner has rejected claims 1, 2, 3, 5, 8, 9, 10, 11 and 12 of the present application under 35 U.S.C. §102(b) as being anticipated by Grossman et al., U.S. Patent No. 5,514,543 ("Grossman"). The rejection is respectfully traversed in light of the foregoing amendments and the following remarks.

i. The Rejection. The present rejection is based on the examiner's contention that each of the elements of the claimed invention are disclosed in Fig. 1A of Grossman. More specifically, at page 2 of the Office Action, the examiner states that,

"The polynucleotide marked (22) is the tag complement. The portion marked (27) is the tail,... . The portion marked (24) is the tag (in this case shown bound to the tag complement). The portion (26) which is not hybridized to the tag complement is the target specific portion... ."

(Office Action, page 3.)